SKP2 and prostate cancer: A novel selenonucleoside (4′-selenofuranosyl-2, 6-dichloropurine, LJ-2618) may bear results in overcoming paclitaxel resistance by promoting Skp2 degradation and stabilizing p27 expression in paclitaxel-resistant prostate cancer [45].